DK1272507T3 - Integrinbindende peptidderivater - Google Patents

Integrinbindende peptidderivater

Info

Publication number
DK1272507T3
DK1272507T3 DK01924011T DK01924011T DK1272507T3 DK 1272507 T3 DK1272507 T3 DK 1272507T3 DK 01924011 T DK01924011 T DK 01924011T DK 01924011 T DK01924011 T DK 01924011T DK 1272507 T3 DK1272507 T3 DK 1272507T3
Authority
DK
Denmark
Prior art keywords
integrin
binding peptide
peptide derivatives
agents
receptors
Prior art date
Application number
DK01924011T
Other languages
Danish (da)
English (en)
Inventor
Bard Indrevoll
Alan Cuthbertson
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009042A external-priority patent/GB0009042D0/en
Priority claimed from GB0025070A external-priority patent/GB0025070D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of DK1272507T3 publication Critical patent/DK1272507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01924011T 2000-04-12 2001-04-06 Integrinbindende peptidderivater DK1272507T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0009042A GB0009042D0 (en) 2000-04-12 2000-04-12 Contrast agents
GB0025070A GB0025070D0 (en) 2000-10-12 2000-10-12 Contrast agents
PCT/NO2001/000146 WO2001077145A2 (en) 2000-04-12 2001-04-06 Integrin binding peptide derivatives

Publications (1)

Publication Number Publication Date
DK1272507T3 true DK1272507T3 (da) 2005-10-03

Family

ID=26244091

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01924011T DK1272507T3 (da) 2000-04-12 2001-04-06 Integrinbindende peptidderivater

Country Status (16)

Country Link
US (2) US7351790B2 (https=)
EP (1) EP1272507B1 (https=)
JP (1) JP5043271B2 (https=)
KR (2) KR100879702B1 (https=)
CN (1) CN1230441C (https=)
AT (1) ATE298763T1 (https=)
AU (2) AU2001250683B2 (https=)
CA (1) CA2405469C (https=)
DE (1) DE60111733T2 (https=)
DK (1) DK1272507T3 (https=)
ES (1) ES2244607T3 (https=)
HK (1) HK1052711A1 (https=)
NO (1) NO331741B1 (https=)
NZ (1) NZ521735A (https=)
PT (1) PT1272507E (https=)
WO (1) WO2001077145A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
CN1230441C (zh) * 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
WO2003084983A1 (en) * 2002-04-11 2003-10-16 Daiichi Suntory Pharma Co., Ltd. Process for producing modified peptide
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
JP2007526300A (ja) 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
CN102532264A (zh) * 2004-06-16 2012-07-04 通用电气医疗集团股份有限公司 基于肽的化合物
JP5280683B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
AU2005265048B2 (en) * 2004-06-18 2011-06-16 Elamleh, David R. Intravascular imaging device and uses thereof
ES2358745T3 (es) * 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
CN101272808B (zh) * 2005-01-06 2012-03-21 通用电气医疗集团股份有限公司 光学成像
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US20100233082A1 (en) * 2006-08-28 2010-09-16 Bengt Langstrom 68GA-Labeled Peptide-Based Radiopharmaceuticals
KR20090097868A (ko) * 2006-12-11 2009-09-16 지이 헬스케어 에이에스 방사선 표지된 펩티드 기재 화합물 및 그의 용도
US20090004119A1 (en) * 2007-06-27 2009-01-01 Ge Healthcare As Polymers
DE102007036570A1 (de) * 2007-08-03 2009-02-19 Siemens Ag Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
JP7174627B2 (ja) * 2015-10-23 2022-11-17 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用
JP7267998B2 (ja) * 2017-08-19 2023-05-02 オハイオ・ステイト・イノベーション・ファウンデーション 新規ペプチド系癌造影剤
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
WO2020230780A1 (ja) * 2019-05-14 2020-11-19 一丸ファルコス株式会社 Ｒａｓ阻害ペプチド

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5198208A (en) 1987-07-16 1993-03-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5753627A (en) * 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1995026205A1 (en) 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
HUP9802675A3 (en) 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
ATE195181T1 (de) 1995-09-11 2000-08-15 Jolla Cancer Res Found Moleküle, die sich in ausgewählten organen oder geweben invivo einfinden und verfahren zu ihrer identifizierung
HUP9901192A3 (en) 1996-01-10 2000-02-28 Amersham Health As Contrast media
EP0907382A1 (de) 1996-02-09 1999-04-14 Steinel GmbH &amp; Co. KG Vorrichtung zum verdunsten eines flüssigen wirkstoffes
WO1998054346A1 (en) 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
EP0927045B1 (en) 1996-09-10 2005-12-14 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
IL137681A0 (en) 1998-02-06 2001-10-31 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
WO1999040214A2 (en) 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
CN1230441C (zh) * 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser

Also Published As

Publication number Publication date
DE60111733T2 (de) 2006-05-18
ATE298763T1 (de) 2005-07-15
DE60111733D1 (de) 2005-08-04
KR20080036662A (ko) 2008-04-28
WO2001077145A2 (en) 2001-10-18
JP5043271B2 (ja) 2012-10-10
HK1052711A1 (zh) 2003-09-26
CA2405469A1 (en) 2001-10-18
AU5068301A (en) 2001-10-23
NO331741B1 (no) 2012-03-19
US20080187493A1 (en) 2008-08-07
EP1272507B1 (en) 2005-06-29
CN1230441C (zh) 2005-12-07
NO20024932D0 (no) 2002-10-14
CA2405469C (en) 2012-03-20
US20030204049A1 (en) 2003-10-30
US7351790B2 (en) 2008-04-01
US8404802B2 (en) 2013-03-26
WO2001077145A3 (en) 2002-05-10
KR20020087973A (ko) 2002-11-23
PT1272507E (pt) 2005-11-30
CN1436195A (zh) 2003-08-13
NZ521735A (en) 2004-12-24
KR100866666B1 (ko) 2008-11-04
ES2244607T3 (es) 2005-12-16
KR100879702B1 (ko) 2009-01-21
EP1272507A2 (en) 2003-01-08
AU2001250683B2 (en) 2006-06-29
JP2003531835A (ja) 2003-10-28

Similar Documents

Publication Publication Date Title
DK1272507T3 (da) Integrinbindende peptidderivater
MXPA04000173A (es) Compuestos basados en peptidos.
NO20040402L (no) Peptidbaserte multimere malrettede kontrastmidler
EP1572639A4 (en) ON INTEGRIN TARGET MEDIUM FOR IMAGE PRESENTATION
MA28843B1 (fr) Therapie d&#39;association utilisant des proteines de fusion de trasferrine comprenant glp-1
BG66085B1 (bg) Фенилаланинови производни
ATE442379T1 (de) Bildgebende agentien auf basis bizyklischer peptide
EP1384220A4 (en) A latent property diagnosing procedure
DE50209802D1 (de) Naht-set für medizinische zwecke
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
NO20073244L (no) Konjugeringsprodukt
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
EP1542721A4 (en) MODIFIED &#34;S&#34; ANTIBODIES
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
EP1664272A4 (en) ENDOTHEL AS A TARGET FOR THE TISSUE-SPECIFIC INTRODUCTION OF AGENTS
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
AU2002339007A1 (en) Preparation of cholecystokinin agonists and antagonists, and their therapeutic and diagnostic use
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
SE9901077D0 (sv) Novel use
WO2008026040A3 (en) 68ga-labeled peptide-based radiopharmaceuticals
DE60117594D1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate